Marker Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 6/6

Marker Therapeutics kazanç ve gelirin sırasıyla yıllık 69% ve 64.3% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 69.9% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 74% olacağı tahmin edilmektedir.

Anahtar bilgiler

69.0%

Kazanç büyüme oranı

69.87%

EPS büyüme oranı

Biotechs kazanç büyümesi	25.5%
Gelir büyüme oranı	64.3%
Gelecekteki özkaynak getirisi	74.00%
Analist kapsamı	Low
Son güncelleme	19 May 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Analiz Makalesi • Jan 12

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analiz Makalesi • Oct 04

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Sep 13

Marker Therapeutics awarded $2M FDA grant for leukemia candidate

Marker Therapeutics, Inc. (NASDAQ:MRKR), a biotech focused on T cell-based immunotherapies, announced Tuesday that the FDA awarded a $2M grant to support its Phase 2 ARTEMIS trial for liquid tumor candidate MT-401 in patients with post-transplant acute myeloid leukemia (AML). MRKR shares added ~10% in the pre-market trading in reaction. MRKR said that the funding awarded under FDA’s Orphan Products Grants program would support the company’s treatment arm designed to test MT-401 in patients with post-transplant AML with minimal residual disease. In 2020, the FDA granted Orphan Drug Designation for MT-401 for treating AML following the allogeneic stem cell transplant. FDA’s Orphan Products Grants program has supported studies that led to the approval of over 70 products. A drug classified as a multi-tumor-associated antigen (MultiTAA) T-cell therapy, MT-401, is currently undergoing the multicenter ARTEMIS trial in patients with AML following an allogeneic stem-cell transplant in both the adjuvant and active disease setting.

Seeking Alpha • Aug 11

Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M

Marker Therapeutics press release (NASDAQ:MRKR): Q2 GAAP EPS of -$0.11 misses by $0.01. Revenue of $0.79M misses by $1.71M. “We are very optimistic about the ability of MT-401 to drive results for patients with measurable residual disease given the results we have seen to date in the ARTEMIS study,” said Dr. Mythili Koneru, Marker’s Chief Medical Officer. “Of note, we were very pleased to note that the second patient we treated with MRD+ disease was found to be MRD- by that patient’s week 8 follow-up. The ability to administer MT-401 without the need for lymphodepletion, coupled with our improved accelerated manufacturing process, enable us to treat patients who have MRD+ disease. We believe that the results observed to date support the notion that patients with AML would have meaningful benefit from a multi-antigen targeted T cell therapy approach.”

Analiz Makalesi • Jun 17

Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analiz Makalesi • Mar 04

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Nov 19

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Seeking Alpha • Oct 22

Marker Therapeutics: Passing Through A Catalyst Desert

MRKR has been trading downwards and sideways for months now. I was asked to see if I can figure out why. It appears that there's a catalyst desert that's been taking its toll on the stock's performance.

Analiz Makalesi • Aug 17

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analiz Makalesi • May 04

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analiz Makalesi • Feb 22

Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?

Every investor in Marker Therapeutics, Inc. ( NASDAQ:MRKR ) should be aware of the most powerful shareholder groups...

Analiz Makalesi • Dec 29

Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:MRKR - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2028	84	15	-24	12	3
12/31/2027	20	-20	-19	-12	3
12/31/2026	3	-19	-10	-10	3
3/31/2026	4	-11	-8	-8	N/A
12/31/2025	4	-12	-12	-12	N/A
9/30/2025	5	-14	-15	-15	N/A
6/30/2025	5	-15	-11	-11	N/A
3/31/2025	6	-13	-13	-13	N/A
12/31/2024	7	-11	-11	-11	N/A
9/30/2024	5	-10	-9	-9	N/A
6/30/2024	4	-10	-11	-11	N/A
3/31/2024	3	-12	-14	-14	N/A
12/31/2023	3	-14	-16	-16	N/A
9/30/2023	3	-14	-20	-20	N/A
6/30/2023	4	-17	-27	-27	N/A
3/31/2023	4	-14	-18	-21	N/A
12/31/2022	4	-20	-27	-27	N/A
9/30/2022	4	-26	-26	-26	N/A
6/30/2022	3	-33	-27	-25	N/A
3/31/2022	2	-43	-36	-31	N/A
12/31/2021	1	-42	-30	-27	N/A
9/30/2021	N/A	-41	-35	-28	N/A
6/30/2021	N/A	-36	-34	-27	N/A
3/31/2021	0	-31	-35	-24	N/A
12/31/2020	0	-29	-29	-20	N/A
9/30/2020	1	-25	-24	-19	N/A
6/30/2020	1	-23	-23	-19	N/A
3/31/2020	0	-23	-19	-19	N/A
12/31/2019	0	-21	N/A	-18	N/A
9/30/2019	N/A	-152	N/A	-20	N/A
6/30/2019	N/A	-151	N/A	-18	N/A
3/31/2019	0	-150	N/A	-16	N/A
12/31/2018	0	-148	N/A	-14	N/A
9/30/2018	0	-15	N/A	-11	N/A
6/30/2018	0	-15	N/A	-9	N/A
3/31/2018	0	-12	N/A	-9	N/A
12/31/2017	0	-11	N/A	-8	N/A
9/30/2017	0	-10	N/A	-8	N/A
6/30/2017	N/A	-8	N/A	-8	N/A
3/31/2017	N/A	0	N/A	-8	N/A
12/31/2016	N/A	-2	N/A	-7	N/A
9/30/2016	N/A	-3	N/A	-6	N/A
6/30/2016	N/A	28	N/A	-5	N/A
3/31/2016	N/A	-38	N/A	-4	N/A
12/31/2015	N/A	-34	N/A	-4	N/A
9/30/2015	N/A	-33	N/A	-4	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: MRKR önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 3.5% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: MRKR önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: MRKR önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: MRKR şirketinin gelirinin (yıllık 64.3% ) US pazarından (yıllık 11.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: MRKR şirketinin gelirinin (yıllık 64.3% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: MRKR 'nin Özsermaye Getirisi'nin 3 yıl içinde çok yüksek olması tahmin ediliyor ( 74 %).

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/20 12:42
Gün Sonu Hisse Fiyatı	2026/05/20 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Marker Therapeutics, Inc. 8 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Yun Zhong	Brean Capital Historical (Janney Montgomery)
Leah Rush Cann	Brookline Capital Markets
John Newman	Canaccord Genuity

Marker Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 6/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

No longer forecast to breakeven

Consensus EPS estimates upgraded to US$0.99 loss

Forecast to breakeven in 2028

Price target decreased by 45% to US$6.00

Consensus revenue estimates increase by 277%

Price target decreased to US$2.17

Recent updates

No longer forecast to breakeven

First quarter 2026 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates upgraded to US$0.99 loss

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Marker Therapeutics, Inc., Annual General Meeting, May 01, 2026

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Forecast to breakeven in 2028

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

New minor risk - Profitability

Marker Therapeutics, Inc. Appoints Kathryn Penkus Corzo to Board of Directors, Effective November 1, 2025

Marker Therapeutics, Inc. Announces Data from Phase 1 APOLLO Study to Present in Two Posters at 67Th American Society of Hematology Annual Meeting and Exposition

Marker Therapeutics, Inc. Announces First Patient Treated in Off-The-Shelf Program

Marker Therapeutics, Inc. Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

Insider recently sold US$148k worth of stock

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Marker Therapeutics Reports That Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

First quarter 2025 earnings released: US$0.40 loss per share (vs US$0.27 loss in 1Q 2024)

Price target decreased by 45% to US$6.00

Marker Therapeutics, Inc., Annual General Meeting, Jun 06, 2025

Full year 2024 earnings: EPS and revenues miss analyst expectations

New major risk - Share price stability

Marker Therapeutics, Inc. Announces Resignation of John Wilson from the Board of Directors

New minor risk - Shareholder dilution

Insufficient new directors

Marker Therapeutics, Inc. announced that it has received $16.1 million in funding

Marker Therapeutics, Inc. announced that it expects to receive $16.1 million in funding

Marker Therapeutics, Inc. Provides Clinical Update on MT-601 in Patients with Lymphoma

Marker Therapeutics Receives $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas to Support the Investigation of Mt-601 in Patients with Pancreatic Cancer

Marker Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $11.431731 million.

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Second quarter 2024 earnings released: US$0.25 loss per share (vs US$0.47 loss in 2Q 2023)

New minor risk - Share price stability

First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.48 loss in 1Q 2023)

New major risk - Revenue and earnings growth

Marker Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Full year 2023 earnings released: US$1.59 loss per share (vs US$3.58 loss in FY 2022)

Marker Therapeutics, Inc. Receives Approval from United States Adopted Name, Council and International Nonproprietary Names Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

New major risk - Share price stability

Marker Therapeutics, Inc. Reports Clinical Update on the Apollo Study

Marker Therapeutics, Inc. Announces Complete Response in First Lymphoma Patient Treated with MT-601 After Car T Relapse

Second quarter 2023 earnings released: US$0.47 loss per share (vs US$1.11 loss in 2Q 2022)

Marker Therapeutics, Inc. Announces Zedenoleucel, Its Multi-Tumor-Associated Antigen (Multitaa)-Specific T Cell Product Candidate, Mt-401

Marker Therapeutics, Inc. Appoints Eliot M. Lurier as Interim Chief Financial Officer

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells After Hypomethylating Agent Administration

Marker Therapeutics, Inc. Reports Pre-Clinical Data of Its MT-601 multiTAA-Specific T Cell Product Candidate in Lymphoma Cells

Marker Therapeutics, Inc. Appoints Monic Stuart, M.D., as Chief Medical Officer

Consensus revenue estimates increase by 277%

Price target decreased to US$2.17

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Marker Therapeutics, Inc. Announces Resignation of Anthony Kim as Chief Financial Officer, Effective September 30, 2022

Marker Therapeutics Wins $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 Artemis Trial of Mt-401 in Post-Transplant AML

Marker Therapeutics awarded $2M FDA grant for leukemia candidate

Nasdaq Grants an Additional 180-Calendar Day Compliance Period to Marker Therapeutics to Regain Compliance with the Minimum Bid Price Requirement

Consensus revenue estimates fall by 41%

Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M

Marker Therapeutics, Inc. Announces FDA Clearance of IND for Mt-601, the Six-Antigen Targeted T Cell Therapy for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

Price target decreased to US$3.63

Marker Therapeutics, Inc., Annual General Meeting, May 24, 2022

Marker Therapeutics, Inc. Announces Frederick Wasserman Will Not Stand for Reelection as Director

Full year 2021 earnings: EPS misses analyst expectations

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Marker Therapeutics, Inc. Announces Clinical Program Updates and Pipeline Expansion

Price target decreased to US$5.63

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics: Passing Through A Catalyst Desert

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics, Inc.(NasdaqGM:MRKR) dropped from Russell 3000E Value Index